News

Both a non-preserved artificial tear containing carboxymethylcellulose 0.5% and cyclosporine ophthalmic emulsion 0.05% are viable options for minimizing dry eye-related discomfort post cataract surgery in "average patients."

A proprietary phaco platform with transversal ultrasound technology has advanced cataract surgery to a new level of safety and efficiency.

A high-powered examination of the effect of an ultrasound probe in the eye during phacoemulsification found among other things that irrigation streams during phaco add a weak repulsive force and that streaming during high-powered longitudinal phaco may also contribute to the phaco effect.

Author Rhonda Fischer wrote her children's book "Randy Kazandy, where are your glasses?" to share a family story and entertain children.

The combination of 1.8-mm coaxial microincision cataract surgery, proper wound construction, and attention to other elements of a surgical technique aiming to maintain chamber stability allows safe and effective cataract surgery in eyes with IFIS without the need for pupil expansion.

Physically active patients who are looking to enhance the enjoyment of their favorite outdoor activity will test your knowledge of performance-specific sunwear.

When failure of the tear pump upsets the dynamic equilibrium between tear production and tear loss, resulting in tearing, numerous options for correction are available.

A typical ophthalmologist or other adult human being is composed of about 100 trillion cells.

Results of a recent study examining adult autopsy globes show that implants fabricated from hydrophobic acrylic material are associated with a much higher rate of posterior capsule opacification than previously thought.

PanOptica Inc. has raised $30 million in financing, coinciding with the company?s successful licensing of exclusive worldwide ophthalmic rights to a selective inhibitor of vascular endothelial growth factor (PAN-90806, OSI Pharmaceuticals) in exchange for up-front cash, equity interest in PanOptica, and potential future milestones and royalties.

Pfizer has obtained an exclusive option for a worldwide license to develop and commercialize Lpath Inc.?s lead monoclonal antibody product candidate (iSONEP), which is being evaluated for the treatment of wet age-related macular degeneration and other eye disorders.

The National Eye Institute has awarded $10.1 million to the Case Western Reserve University School of Medicine to research and develop new treatments for retinal diseases.

The merger of Alcon Inc. and Novartis AG is expected to be completed during the first half of this year after it was announced that the companies have entered into an agreement whereby Novartis will pay $168 per share for the Alcon shares it currently does not own.

The FDA has requested additional information to aid in its decision of whether to approve a new drug application for an investigational fluocinolone acetonide intravitreal insert (Iluvien, Alimera Sciences) for the treatment of diabetic macular edema.

Bausch + Lomb (B+L) has voluntarily recalled an eye drop (Soothe Xtra Hydration) after receiving from consumers ?a small number? of reports of particles, which the company later identified as mold, in the tips of the bottles.

Fortunately, in most medical practices, angry patients are the exception, not the norm.

An age-adjusted retinal nerve fiber layer thickness normative database for a proprietary ocular coherence tomography device gives clinicians a tool for assessing glaucoma risk from a patient's first visit, according to one expert.

Achieving optic nerve regeneration is far from becoming reality.

Lower corneal hysteresis is associated with worse glaucomatous damage independent of its effect on IOP measurement, and may be the best indicator of the eye with worse visual field loss.

A specific diode laser with its versatility is one of the latest technologies available for laser trabeculoplasty.

In a review of what has changed in the more than 35 years since he became interested in open-angle glaucoma, Alfred Sommer, MD, MHS, provided his insights during glaucoma subspecialty day at the AAO.

A year after Novartis AG announced its intention to acquire the controlling shares of Alcon Inc., the companies have agreed on merger terms that raise the offer to minority shareholders of the world's largest eye-care company by $15 per share.

The impending availability of generic latanoprost is creating much discussion about the potential effect on the prescribing of IOP-lowering medications.

Results of an in vitro study of the potentially adverse effects of different topical glaucoma medications and preservatives showed that the preservatives polyquad and sofZia had much less toxicity when used in place of benzalkonium chloride in prostaglandin analogue formulations.

After putting physicians on the brink of a massive pay cut 5 times during 2010, legislation has been passed that buys a year of stability while a better method is sought for paying those who treat Medicare patients.

The lack of randomized, controlled clinical trials of blepharoplasty and ptosis repair leaves oculoplastics open to challenge for reliance on anecdotal evidence of the efficacy of common surgical procedures.

A glaucoma filtration device has several advantages that compare favorably with trabeculectomy.

Evaluating both the genomic and proteomic biomarkers combined seems the most effective method to determine age-related macular degeneration risk and the likelihood of progression to advanced AMD.